Get started
ALLIGATOR BIOSCIENCE ABALLIGATOR BIOSCIENCE ABALLIGATOR BIOSCIENCE AB

ALLIGATOR BIOSCIENCE AB

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Seasonals

ATORX fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Alligator Bioscience AB is a biotechnology company, which engages in the development of novel immuno-oncology drugs. The firm specializes in the development of tumor-directed immunotherapies. Its pipeline includes Mitazalimab, ATOR-1017, ALG.APV-527, Neo-X-Prime, and other research projects. The company was founded by Carl Arne Krister Borrebaeck in 2001 and is headquartered in Lund, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ATORX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company